SCHEMBL23926360

SCHEMBL23926360

Cc1ccc(O)c(-c2nc(-c3cc(F)ccc3O)n3c2CCCC3)n1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.35
RORC P51449 8/20 0.34
APP P05067 2/20 0.34
NPC1 O15118 1/20 0.34
CHEK2 O96017 1/20 0.34
PPARG P37231 2/20 0.33
KDM4E B2RXH2 4/20 0.32
TDP1 Q9NUW8 2/20 0.32
HTT P42858 1/20 0.32
HPGD P15428 3/20 0.32
THRB P10828 1/20 0.32
TGFBR1 P36897 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HSD17B10 Q99714 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
USP2 O75604 1/20 0.32
LMNA P02545 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30118899 1.00 TP53 (0.35) TP53RORCAPPNPC1CHEK2
SCHEMBL23926361 0.88 ALDH1A1 (0.37) TP53RORCAPPKDM4ETDP1
SCHEMBL30118892 0.88 ALDH1A1 (0.37) TP53RORCAPPKDM4ETDP1
SCHEMBL30118953 0.85 KDM4E (0.41) TP53RORCNPC1KDM4ETDP1
SCHEMBL23926351 0.85 KDM4E (0.41) TP53RORCNPC1KDM4ETDP1
SCHEMBL23926341 0.82 RORC (0.38) TP53RORCPPARGKDM4ETHRB
SCHEMBL30118929 0.82 RORC (0.38) TP53RORCPPARGKDM4ETHRB
SCHEMBL23926379 0.81 KDM4E (0.39) APPCHEK2KDM4ETDP1HPGD
SCHEMBL30118895 0.81 KDM4E (0.39) APPCHEK2KDM4ETDP1HPGD
SCHEMBL23926372 0.80 RORC (0.37) TP53RORCKDM4ETDP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4168408-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2023-04-26 EP disclosed
CN-115667256-A Compounds for treating diseases and methods of treating diseases 艾特里提治疗有限公司 2023-01-31 CN disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155547-B1 Compounds for and methods of treating diseases HTT, SNCA, PARK7 TP53 3349/4885RORC 1253/4885APP 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.